# Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

> **NCT02899169** · PHASE3 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 110 (estimated)

## Conditions studied

- Acute Promyelocytic Leukemia

## Interventions

- **DRUG:** Realgar-Indigo naturalis formula
- **DRUG:** all-trans retinoic acid
- **DRUG:** Arsenic trioxide
- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT02899169
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2021-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02899169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02899169, "Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02899169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*